Relenza Use In U.K. For 2000 Season Will Await Four Ongoing Glaxo Trials
Executive Summary
A recommendation in favor of prescribing Glaxo Wellcome's influenza therapy Relenza on the U.K.' s National Health Service for the 2000-20001 flu season will await the results of four ongoing trials, according to a report issued Oct. 8 by the National Institute for Clinical Excellence.
You may also be interested in...
Relenza Prophylaxis Indication Withdrawn In EU; Pediatric Use Cleared In U.S.
Glaxo Wellcome's influenza medication Relenza for prevention of flu was withdrawn from the EU mutual recognition process so the company could resubmit the application with more data in elderly and high-risk patients, Glaxo said.
Relenza Prophylaxis Indication Withdrawn In EU; Pediatric Use Cleared In U.S.
Glaxo Wellcome's influenza medication Relenza for prevention of flu was withdrawn from the EU mutual recognition process so the company could resubmit the application with more data in elderly and high-risk patients, Glaxo said.
Roche Withdraws Tamiflu European Application; Will Submit More Flu B Data
Roche will submit additional Tamiflu data supporting the drug's efficacy against influenza B after withdrawing its European application for the neauraminidase inhibitor.